Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: A randomized trial.

Antonino Tuttolomondo (✉ bruno.tuttolomondo@unipa.it)  
Università degli Studi di Palermo Scuola di Medicina e Chirurgia  
https://orcid.org/0000-0001-6440-7318

Anna Cirrincione  
University of Palermo

Alessandra Casuccio  
University of Palermo

Alessandro Del Cuore  
Università degli Studi di Palermo Dipartimento di Scienze Economiche Aziendali e Statistiche

Mario Daidone  
Università degli Studi di Palermo Dipartimento di Scienze Agrarie e Forestali

Tiziana Di Chiara  
University of Palermo

Domenico Di Raimondo  
University of Palermo: Università degli Studi di Palermo

Vittoriano Della Corte  
University of Palermo: Università degli Studi di Palermo

Carlo Maida  
Università degli Studi di Palermo Dipartimento di Scienze Agrarie e Forestali

Irene Simonetta  
University of Palermo

Stefania Scaglione  
Università degli Studi di Palermo Dipartimento di Scienze Agrarie e Forestali

Antonio Pinto  
Università degli Studi di Palermo Dipartimento di Scienze Agrarie e Forestali

Original investigation

Keywords: dulaglutide, vascular health, diabetes

DOI: https://doi.org/10.21203/rs.3.rs-51124/v2
Abstract

**Background:** Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiovascular risk validated by some studies include arterial stiffness and endothelial function indexes. To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on endothelial and arterial stiffness indexes as surrogate markers of vascular damage.

**Aims:** We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.

**Methods:** Men and women (aged ≥50 years) with established or newly detected type 2 diabetes whose HbA1c level was 9.5% or less on stable doses of up to two oral glucose lowering drugs with or without basal insulin therapy were eligible for randomization. Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly). Arterial stiffness (PWV: pulse wave velocity and augmentation index) and endothelial function (RHI: reactive hyperaemia index) were evaluated at baseline and at three-month and nine-month examination visits. At each visit (at 3 and 9 months), the subjects were also evaluated for glycaemic variables such as fasting plasma glucose (FPG) and HbA1c and lipid variables such as total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride levels.

**Results:** At the three-month follow-up, the subjects treated with dulaglutide showed significantly lower serum levels of FPG and HbA1c than control subjects treated with conventional therapy. At the 9-month follow-up, subjects treated with dulaglutide showed significant lower values of the mean diastolic blood pressure, BMI, total serum cholesterol, LDL cholesterol, FPG, HbA1c and PWV and higher mean RHI values than control subjects treated with conventional therapy.

**Conclusions:** Our randomized trial showed that subjects with type 2 diabetes treated with conventional therapy plus 1.5 mg/day of subcutaneous dulaglutide compared with subjects treated with conventional therapy alone showed favourable metabolic effects associated with positive effects on vascular health markers such as arterial stiffness and endothelial function markers. These findings are consistent with previous study findings indicating the strict relationship between cardiovascular risk factors such as systolic blood pressure, total serum cholesterol and LDL levels and cardiovascular events and vascular health surrogate markers.

**Background**

Glucagon-like peptide-1 (GLP-1) is a member of an endogenous class of incretin hormones synthesized in intestinal epithelial cells in response to gastrointestinal nutrients (1). GLP-1 enhances glucose-dependent secretion of insulin (2,3), inhibits glucagon secretion (4), slows gastric emptying (5) and reduces food intake (6).
Dulaglutide (Eli Lilly and Co., Indianapolis, IN, USA), a long-acting GLP-1 receptor agonist (7), mimics some endogenous GLP-1 effects. Dulaglutide has been approved in the USA and European Union at once-weekly doses of 0.75 and 1.5 mg as a subcutaneous injection to improve glycaemic control in patients with type 2 diabetes.

In global clinical trials completed to date, dulaglutide (1.5 mg) is superior to metformin, sitagliptin and exenatide twice daily and non-inferior to liraglutide (1.8 mg) for glycated haemoglobin (HbA1c) changes (8-11).

Endothelial dysfunction and an abnormal vascular structure may represent complications of diabetes. Substantial clinical and experimental evidence suggests that both diabetes and insulin resistance cause a combination of endothelial dysfunction, which may diminish the anti-atherogenic role of the vascular endothelium (12-14).

The initiation and progression of atherosclerosis may originate from impaired endothelial function detected at the earliest stages of the syndrome. The elements of the metabolic syndrome and accelerated phases of atherogenesis are often silent partners that present many years before the onset of type 2 diabetes mellitus. The ability to detect subclinical vascular disease, reflected as multiple factors that impair arterial wall integrity, offers new tools to refine cardiovascular risk stratification (15). Endothelial dysfunction in peripheral arteries is evaluated by forearm flow-mediated vasodilation (FMD) (18). However, this technique offers findings that can widely vary due to technical problems, limiting its use as a fully standardized method (19).

Kuvin et al. (20) described a new method to evaluate endothelial dysfunction, called reactive hyperaemia peripheral arterial tonometry (RH-PAT). This method measures the hyperaemic response non-invasively. The Framingham Heart Study reported that RHI (reactive hyperaemia index) is inversely related to various cardiovascular risk factors (21), confirming the usefulness of this test.

Arterial stiffness indexes, such as the augmentation index (AIx) and pulse wave velocity (PWV), have been reported as surrogate cardiovascular markers (22), whereas endothelial dysfunction has been reported as an associated factor (21).

Adjunctive surrogates for cardiovascular risk validated by some studies more recently (23, 24) are arterial stiffness and endothelial function indexes.

Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events using these glucagon-like peptide (GLP)-1 receptor agonists (13-16).

Progressive separation of the treatment and placebo curves, starting clearly between 12 and 18 months of the trial period, as well as significant reductions in the risk of myocardial infarction and stroke, indicate that the beneficial CV effects observed using GLP-1 receptor agonists could be due to an anti-atherogenic effect (17).
The use of glucose-lowering agents is an effective strategy to prevent vascular complications, but the extent to which it can reduce CV complications is less certain. Glucagon-like peptide-1 (GLP-1) agonists are potent glucose-lowering agents but also have potentially beneficial effects on other traditional (body weight, blood pressure (BP), and LDL cholesterol) and non-traditional risk factors (low-grade inflammation and endothelial dysfunction).

Our group recently reported that, in some cohorts of patients, such as patients with diabetic foot (25), subjects with NAFLD (26) and patients with acute ischaemic stroke (27), higher mean values of arterial stiffness markers (PWV, Alx) and lower mean values of reactive hyperaemia indexes (RHI) may be considered surrogate markers of vascular damage.

A previous recent study on a small sample of patients showed that once-weekly dulaglutide was comparable to once-daily liraglutide in terms of its effects on oxidative stress and endothelial function, as measured by RHI (28).

To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on endothelial function, as measured by RHI, and arterial stiffness indexes, such as surrogate markers of vascular damage.

**Study Hypothesis**

Our study hypothesis is that the anti-atherogenic effect and consequent beneficial cardioprotective profile of dulaglutide may be related to its metabolic efficacy and possible efficacy on vascular health indexes such as endothelial dysfunction and arterial stiffness markers.

**Objective of the study**

In the present randomized trial, we compared once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment with traditional treatment alone using surrogate vascular efficacy endpoints such as endothelial function and arterial stiffness indexes and metabolic efficacy endpoints.

**Aims and endpoints**

The first aim of the study was to show the superiority of dulaglutide vs traditional treatment for vascular health indexes such as markers of arterial stiffness (PWV, Alx) and endothelial function such reactive hyperaemia index (RHI) changes from baseline at the three- and nine-month follow-ups.

The second aim of the study was to show the superiority of dulaglutide vs traditional treatment for changes in metabolic variables (*fasting plasma glucose*, HbA1c, *total cholesterol*, *LDL-cholesterol*, *HDL-cholesterol*, and *triglyceride levels*) from baseline at the three- and nine-month follow-ups.

The vascular efficacy endpoints were as follows:

- *change from baseline in the RHI value at the three- and nine-month follow-ups*
change from baseline in PWV at the three- and nine-month follow-ups
change from baseline in Alx at the three- and nine-month follow-ups

The metabolic efficacy endpoints were as follows:

- change from baseline in body weight at the three- and nine-month follow-ups
- change from baseline in BMI at the three- and nine-month follow-ups
- change from baseline in FPG at the three- and nine-month follow-ups
- change from baseline in HbA1c at the three- and nine-month follow-ups
- change from baseline in the serum total cholesterol at the three- and nine-month follow-ups
- change from baseline in the serum LDL cholesterol at the three- and nine-month follow-ups
- change from baseline in the serum HDL cholesterol at the three- and nine-month follow-ups

Materials And Methods

Study Design and Participants

This study was a single-centre, 9-month randomized trial designed to evaluate the efficacy of antidiabetic traditional treatment + dulaglutide compared with traditional antidiabetic treatment alone in patients with type 2 diabetes.

Traditional antidiabetic treatment was considered treatment with metformin or metformin plus sulfonylurea or basal insulin plus metformin.

Men and women (aged ≥ 50 years) with established or newly detected type 2 diabetes whose HbA1c level was 9.5% or less on stable doses of up to two oral glucose lowering drugs with or without basal insulin therapy were eligible.

The key exclusion criteria for the screened patients were as follows: type 1 diabetes, previous GLP-1 receptor agonist treatment, treatment with more than half of the sulphonylurea maximum dose at screening, chronic systemic glucocorticoid use, or gastric emptying abnormality.

Further exclusion criteria were an eGFR value less than 15 mL/min per 1.73 m², cancer in the last 5 years, severe hypoglycaemia in the last year, a life expectancy of less than 1 year, a coronary or cerebrovascular event within the last 2 months, and plans for revascularization.

A common protocol was approved by the institutional review board, and the study was performed in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice (29).

Each patient provided written informed consent before participation.

The trial has been registered on Clinical Trials.gov [ClinicalTrials.gov Identifier: NCT03824002].
We used the revised criteria of the American Diabetes Association to diagnose type 2 diabetes (T2DM)—a fasting blood glucose value ≥126 mg/dl or a clinically based algorithm that considered presenting weight and symptoms, age at onset, onset of insulin treatment, family history and history of ketoacidosis (30).

Hypertension was diagnosed according to the 2013 ESC-ESH criteria (31).

Dyslipidaemia was defined as a TG level ≥150 mg/dl and HDL cholesterol level <40 mg/dl regardless of the patient’s gender (32).

**Randomization**

After a 2-week placebo screening and run-in period, eligible patients were randomly assigned to undergo traditional antidiabetic treatment plus dulaglutide or traditional antidiabetic treatment alone using a computer-generated random sequence (1:1) with dulaglutide administered once weekly for 9 months. The investigators involved in clinical data collection and the measurement of outcome variables were not directly involved in the patients’ treatment and were masked to the randomization process. The randomization code was maintained only at the central data facility and was not broken until all data analysis was complete.

**Procedures**

Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).

During the treatment period, participants in the dulaglutide group were instructed to inject the study drug on the same day at approximately the same time each week. The participants were visited at 2 weeks, 3 months, and 9 months. At every visit, assessments included cardiovascular events, adverse events, vital signs, and periodic questionnaires, laboratory test electrocardiograms (ECGs) and vascular damage index assessment (see above). Investigators were advised to promote a healthy lifestyle and manage glucose concentrations according to local guidelines. The management of blood pressure, lipids, other cardiovascular risk factors, and medical conditions was at the discretion of the study investigator.

Hypoglycaemia was defined as a blood glucose concentration ≤3.9 mmol/l. Severe hypoglycaemia was defined as an episode that required the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions. The patients were allowed to initiate rescue therapy for severe, persistent hyperglycaemia according to predefined thresholds of fasting blood glucose for at least 2 weeks with no readily identifiable cause.

**Methods of measurement**

**Measurement of the heart rate at rest**
According to the Consensus Panel of the European Society of Hypertension (32) the following information should be provided in studies reporting heart rate data: (i) resting period before measurement; (ii) environmental conditions; (iii) method of measurement; (iv) number of measurements; (v) duration of measurement; (vi) body position; and (vii) nature of the observer. The table shows the recommendations provided by the panel regarding how the heart rate should be measured.

To achieve a stable haemodynamic condition, the patient should rest for at least 5 minutes, although subjects with a pronounced white-coat reaction may require a longer period. The duration of measurement ranges from 15 seconds to 1 minute in different studies. According to the European consensus panel (32), 30 seconds is sufficient to obtain a reliable estimate of the heart rate because, in most patients, 30 to 40 cardiac cycles can be averaged. In subjects with a very low heart rate, a longer period may be necessary. Two measurements were considered sufficient for a reliable estimate of the resting heart rate in most patients.

**Measurement of the blood pressure**

According to the Consensus Panel of the European Society of Hypertension (32), the recommended steps to measure blood pressure in our enrolled patients were:

- The patients were on a sitting position (comfortable, relaxed, legs uncrossed, feet resting on the floor) for 5 minutes before obtaining the measurement
- The arm should be supported at the level of the heart and slightly flexed at the elbow
- The BP cuff is placed with the bladder midline over the brachial artery pulsation

The lower border of the cuff should be approximately 2.5 cm above the antecubital crease

- To determine the inflation level, the radial artery is palpated and the cuff is rapidly inflated until the pulse disappears; this pressure was recorded from the manometer and 30 mmHg was added to the value
- The cuff is deflated, followed by a delay for 15–30 seconds
- The stethoscope is placed lightly over the brachial artery
  
  a. The Korotkoff sounds are best heard with the bell of the stethoscope because they are relatively low in pitch
  
  b. A proper seal is confirmed

- The cuff is inflated rapidly to the predetermined inflation level (see step 4)
- The bulb’s screw is turned counter-clockwise to deflate slowly at a rate of 2-3 mmHg/second
- The level is recorded at which the sounds of at least two consecutive beats are heard (Korotkoff phase I). This value represents the patient's systolic BP
The cuff is allowed to deflate until the sounds become muffled and disappear (Korotkoff phase V). This value represents the patient's diastolic blood pressure.

- The cuff is deflated rapidly
- The systolic and diastolic levels are read to the nearest 2 mmHg
- The blood pressure, arm used, arm position, and cuff size are recorded
- The operator waits \( \geq 2 \) minutes if measurements are repeated

**PWV Measurement**

Carotid-femoral PWV was assessed in the supine position using an automatic device (SphygmoCor version 7.1) that evaluated the time delay between the rapid upstroke of the carotid and femoral artery pulse waves. The distance between the two arterial points was measured using a tape measure on the surface of the body. PWV was valuated as the distance travelled by the arterial pulse wave (metres) divided by the time delay between the two arterial points (seconds), expressed as metres per second.

**Pulse Wave Analysis**

We used applanation tonometry to record the radial artery pressure waveform continuously, and mean values \( \geq 2 \) screens of pulse waves of good quality were used for analysis. Considering the collected data, an averaged radial pressure waveform was created and a corresponding aortic pressure waveform and BP were calculated using the validated transfer function (SphygmoCor version 7.1). The aortic pressure waveform was utilized to calculate the AIx (difference in height between the first and second systolic peaks, expressed as a percentage of PP).

**RH-PAT**

The principle of RH-PAT has been described previously (19). Briefly, a blood pressure cuff was positioned on 1 upper arm, while the contralateral arm served as a control. PAT probes were positioned on one finger of each hand. After a 5-min equilibration period, the cuff was inflated to 60 mm Hg above the systolic pressure or 200 mm Hg for 5 min and then deflated to induce reactive hyperaemia. Reactive hyperaemia is a temporary increase in blood flow in an area due to induced ischaemia and reflects ‘the health state’ of the endothelium.

The RH-PAT data were digitally analysed online using Endo-PAT2000 software version 3.0.4. The RH-PAT index (RHI: reactive hyperaemia index) reproduces the range of reactive hyperaemia and is measured as the ratio of the mean amplitude of the PAT signal over 1 min starting 1.5 min after cuff deflation (control arm, A; occluded arm, C) divided by the mean amplitude of the PAT signal of a 2.5-min time period before cuff inflation (baseline) (control arm, B; occluded arm, D). Thus, RH-PAT index (RHI) = (C/D)/(A/B) \times baseline correction. A value of RHI < 1.67 indicated endothelial dysfunction.

**Vascular damage marker evaluation**
PWV, Alx and RHI were measured at admission and every three- and nine-month follow-up visit assessment.

**Statistical Analysis**

The sample-size (performed by IBM SPSS SamplePower 3) of at least 40 randomized patients was selected to provide >99% power to demonstrate superiority of dulaglutide respect to conventional therapy alone. This assumed a true mean difference in metabolic and vascular variable mean value change from baseline between dulaglutide and placebo of 0.8%, a common standard deviation of 1.1%, a one-sided significance level of 0.025, and a 9% drop-out rate between randomization and week (26). Moreover, the given sample-size provided at least 90% power to confirm non-inferiority of dulaglutide to liraglutide with a margin of 0.4%.”

Continuous data were expressed as the means ±SD, unless otherwise specified. Intergroup differences were assessed by chi-squared test or Fisher’s exact test, as needed for categorical variables, and by independent Student’s t test for continuous parameters if the data were normally distributed. Intragroup differences were performed by repeated measures analysis of variance (ANOVA), and post-hoc analysis with Tukey’s test was used to determine if there were any intra-group differences in pairs.

The data were analysed using IBM SPSS Software 22 version (IBM Corp., Armonk, NY, USA). All p-values were two-sided, and p<0.05 was considered statistically significant.

**Results**

From April 2, 2017 to April 12, 2019, 124 patients entered the study: 60 were randomized to treatment with the study drug (56 completed 3 months and 9 months of treatment), and 64 were control subjects. Twelve patients (4 in the group with traditional treatment plus dulaglutide and 8 in the control group) discontinued the study, with ‘withdrawal by subject’ being the most common reason.

The patient demographics and baseline characteristics were similar between the groups (Table 1).

At the end of the randomization phase, 56 patients completed the study for each group.

At baseline, the patients treated with dulaglutide plus traditional therapy and control subjects treated with traditional therapy showed no significant difference regarding age (69.7 ± 8.6 years vs 67.6 ± 5.1 years, respectively; p=0.111), duration of diabetes (10.4 ± 3.3 years vs 10.2 ± 4.0 years, respectively; p=0.773), mean fasting plasma glucose (FPG) (147.6 ± 32.5 mg/dl vs 144.6 ± 31.5 mg/dl, respectively; p=0.626), mean HbA1c (7.4 ± 0.7% ± 7.2 ± 0.6%, respectively; p=0.101), mean total cholesterol (160.9 ± 20.5 mg/dl vs 167.8 ± 25 mg/dl mmol/L; p=0.121), mean HDL cholesterol (37.4 ± 4.3 mg/dl vs 37.5 ± 4.5 mg/dL, respectively; p=0.961), mean LDL cholesterol (102.7 ± 11.6 mg/dl/2.65 ± 0.3 mmol/L vs 104.5 ± 13.6 mg/dl/2.7 ± 0.35 mmol/L, respectively; p=0.439), mean triglyceride level (139.2 ± 13.6 mg/dl vs 138.90 ± 13.58 mg/dl, respectively; p=0.910), mean RHI (1.7 ± 0.4 vs 1.8 ± 0.7, respectively; p=0.275), and PWV (11.2 ± 0.91 m/sec vs 10.9 ± 0.8 m/sec, respectively; p=0.193) (see table 1).
The subjects treated with dulaglutide and control subjects treated with traditional therapy showed no significant differences regarding the other clinical and laboratory variables at baseline.

**Efficacy**

At the three-month follow-up, the subjects treated with dulaglutide, compared with control subjects treated with conventional therapy, showed no significant difference concerning SBP, DBP, BMI, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, GFR CKD-EPI, and microalbuminuria, but they showed a significantly lower body weight (73.1± 7.6 kg vs 76.6±7.1 kg, respectively; p=0.014), significantly lower serum levels of FPG (131.2 ± 21.95 mg/dl vs 146.2 ±29.5 mg/dl, respectively; p=0.003) and a significantly lower percentage of mean HbA1c (6.5 ± 0.5% vs 7.0 ± 0.5%, respectively; p<0.0005) (table 2).

At the nine-month follow-up, the subjects treated with dulaglutide, compared with control subjects treated with traditional therapy, showed a significantly lower mean DBP value (71.8 ± 9.2 mm/Hg vs 75.9 ± 9.7 mm/Hg, respectively; p=0.026), body weight (68.9 ± 5.6 kg vs 76.3 ± 13.84 mm/Hg, respectively; p=0.015), BMI (25.2 ± 3.6 kg/m² vs 27.8 ± 5.1, respectively; p=0.03), mean total serum cholesterol (152.3 ± 22.4 vs 163.3±21.5 mg/dl, respectively; p=0.009), mean LDL serum cholesterol (96.0±9.1 mg/dl vs 103.2±10.8 mg/dl, respectively; p<0.0005), FPG (119.3 ± 14.3 mg/dl vs 145.5 ± 29.6 mg/dl, respectively; p <0.0005), Hba1c (6.2 ± 0.3% vs 6.9 ± 0.5%, respectively; p <0.0005), microalbuminuria (79.1 ± 9.0 vs 82.5 ± 9.3 mg/dl, respectively; p=0.05), mean PWV (10.6 ± 0.8 m/sec vs 11.0 ±0.6, respectively; p=0.015) and a higher mean RHI value (2.0 ± 0.4 vs 1.8 ± 0.4, respectively; p=0.023) (table 2).

Intragroup analysis showed that subjects treated with once-weekly dulaglutide at the 9 month follow-up showed a significantly lower mean SBP than at baseline and the three-month follow-up, (129.7 ± 10.71 mm/Hg vs 137.8 ± 12.1 mm/Hg vs 134.9 ± 10.9 mm/Hg, respectively; p<0.0005), mean DBP (71.9 ± 9.29 mm/Hg vs 76.3 ± 12.2 vs 73.2 ± 9.99, respectively; p=0.03), weight (68.9 ± 8.8 kg vs 73.1± 7.6 kg vs 75.8± 8.5 kg, respectively; p <0.0005), BMI (25.2 ± 3.6 kg/m² vs 26.9 ± 3.4 kg/m² vs 27.6 ± 3.4 kg/m², respectively; p<0.0005), mean FPG values (119.3 ± 14.3 mg/dL vs 147.6 ±32.5 mg/dl vs 131.2 ± 21.9 mg/dl, respectively; p<0.0005), mean Hba1c percentage (6.2± 0.3% vs 6.5 ± 0.4 vs 7.3± 0.7%, respectively; p<0.0005), total cholesterol (152.3 ± 22.4 mg/dl vs 160.3 ±21.2 mg/dl vs 160.9± 20.5 mg/dl, respectively; p=0.04), mean LDL cholesterol (96.0 ± 9.1 mg/dl vs 102.7 ±11.6 mg/dl vs 101.8±10.6 mg/dl, respectively; p=0.001), mean PWV (10.6±0.8 m/sec vs 11.2±0.9 m/sec vs 10.8±0.8 m/sec, respectively; p<0.0005), mean AIX (101.8±5.3% vs 105.6 ± 6.9% vs 103.1±6.7%, respectively; p= 0.001) and significantly higher median RHI values (2.0 ± 0.4 vs 1.7 ± 0.44 vs 1.8 ± 0.4, respectively; p=0.005) (table 3).

**Discussion**

This study aimed to examine the efficacy in ameliorating endothelial and arterial stiffness markers of once-weekly dulaglutide (1.5 mg) plus traditional therapy in diabetic patients with type 2 diabetes.
Our study is the first to analyse the efficacy of dulaglutide therapy on surrogate vascular endpoints such as endothelial and arterial stiffness indexes in parallel with metabolic effects.

Consistent with previous studies, we demonstrate that subjects treated with traditional therapy plus dulaglutide showed significantly lower mean fasting plasma glucose and glycated haemoglobin levels at the three- and nine-month follow-ups. Thus, our study further confirms previous findings concerning the reduction of glucose serum levels and HbA1c serum levels (33-34).

Grunberger et al (35) demonstrated a dose-dependent HbA1c reduction for dulaglutide and greater reduction than placebo. Furthermore, the multicentre, randomized, placebo-controlled REWIND study (36) that recruited participants who aged at least 50 years with type 2 diabetes, a haemoglobin A1c (HbA1c) level of 9.5% or less, and a body mass index greater than 23 kg/m$^2$ reported that the HbA1c levels were reduced in the drug group by a mean of –0.61% compared with placebo (34).

Our study also reported that subjects treated with traditional therapy plus dulaglutide showed a significantly lower mean body weight and, BMI and significantly lower mean LDL cholesterol and total cholesterol serum levels at the nine-month follow-up.

In the REWIND study, subjects with type 2 diabetes who had a previous cardiovascular event or cardiovascular risk factors and were randomly assigned to either weekly subcutaneous injection of dulaglutide (1.5 mg) or placebo showed lower total cholesterol and lower LDL cholesterol at follow-up (36).

Atherogenic dyslipidaemia in diabetes in type 2 diabetes is characterized by the overproduction and/or delayed catabolism of triglyceride-rich particles (TRLs), including apolipoprotein apo-B-48 containing chylomicrons and apo-B100-containing VLDLs, cholesterol-rich remnant particles, small dense LDLs and a reduction in circulating HDLs (37). When the number of postprandial TRLs is reduced in response to the induction of GLP-1 signalling, GLP-2 receptor activation is involved in the promotion of lipid absorption (38). In experimental hamsters, an infusion of GLP1 and GLP2 causes an initial increase in lipid absorption and increased plasma concentrations of TRL-apo B48 in plasma and this response in terms of the increased postprandial lipid response has been reported to be enhanced under the condition of insulin resistance, such as in type 2 diabetes (39).

We also reported that subjects treated with traditional therapy plus dulaglutide showed significantly lower mean body weight, SBP, and DBP values at the nine month follow-up. Furthermore, at nine months, we observed a significant reduction in the levels of microalbuminuria, a well-known marker of vascular damage in diabetes (38,39).

Regarding patients enrolled in the REWIND trial, their weight decreased by a mean of –1.5 kg while the systolic blood pressure and LDL cholesterol levels were slightly lower in the drug group (40).
In our trial, the metabolic effects on FPG and HbA1c were observed earlier at three months. By contrast, at nine months, we observed more delayed effects on cholesterol serum variables and vascular health indexes such as RHI and arterial stiffness indexes such as PWV and Alx, possibly indicating a more strict relationship between vascular damage markers and cholesterol serum levels.

These findings are consistent with previous studies indicating the strict relationship between cardiovascular risk factors such as systolic blood pressure, total serum cholesterol and LDL levels (41-43) and cardiovascular events and vascular health surrogate markers (44).

Furthermore, as observed in our trial, and similarly in recent studies (36,45), weekly subcutaneous injection of 1.5 mg of dulaglutide was associated with weight loss and consequently a reduction in the BMI.

A chronic inflammatory state linked to obesity leads to dysregulation of the endocrine and paracrine actions of adipocyte-derived factors, which disrupt vascular homeostasis and contribute to endothelial vasodilator dysfunction by determining, among other effects, an imbalance in the endothelin-1/nitric oxide pathway (46).

Considering these premises, the reduction of body weight and BMI observed in the dulaglutide arm at the nine-month follow-up might lead to a reduction in the systemic inflammatory state, the resumption of the correct mechanisms of vascular homeostasis and, as observed in our trial, an improvement in the vascular health indexes.

Several studies have indicated that, in addition to lowering glucose, dulaglutide affected the cardiovascular system (41-44). These investigators reported that patients with T2DM found that dulaglutide could lower systolic blood pressure by 2.8 mmHg compared with placebos. Tuttle et al., in a study of 6,005 patients with T2DM, showed that dulaglutide slightly lowered the urine protein level but did not lower the glomerular filtration rate (42).

Furthermore, Ceriello et al. showed a beneficial effect of the combination of GLP-1-RA and insulin on hyperglycaemia-induced oxidative stress and endothelial function for patients with T2DM (43). The antioxidant properties of GLP-1-RA increases intracellular antioxidant defences (44). This mechanism may be due to the use of a GLP-1-RA affecting oxidative stress and vascular endothelial function characteristics. Another reason may be that glycaemic control is better in patients treated with dulaglutide plus conventional therapy and possibly related to an improvement in glucose variability, as reported by some studies (47).

Consistent with previous study finding (36, 50), our findings underlined the efficacy of dulaglutide on glycaemic control, as shown by its precocious action on lowering FPG and HbA1c not only at nine months but also at three months.

A previous study (47) demonstrated that the reduction of FPG and improvement in glycaemic variability are correlated with the reduction of oxidative stress on the vascular endothelium.
In particular, an increase in FPG and glucose variability can induce the worsening of oxidative stress through many mechanisms, including ROS overproduction mediated by many pathways, such as the increase in AGE levels, vasomotor imbalance mediated by the reduction of NO availability and increase in the oxidant peroxynitrite, increased inflammation molecules and overexpression of cellular adhesion molecules on the endothelial surface, such as ICAM, VCAM, and E-selectin, which promote inflammation by leukocyte rolling (48). These pathways may contribute to endothelial dysfunction and accelerate the process of atherosclerosis, leading to increased cardiovascular events (49).

Moreover, our study showed improvement in endothelial markers such as RHI, AIx and PWV at nine months. Thus, our findings of the precocious reduction of FPG and HbA1c at three months, owing to their possible negative action on the modulation of oxidative stress, should provide an interesting explanation for the improved endothelial function, as suggested by an increase in RHI and a decrease in PWV and AIx at nine months.

Furthermore, because the treatment and placebo curves in the REWIND were separated, starting clearly between 12 and 18 months of the trial treatment period, the beneficial vascular effect of the GLP-1 receptor agonists could be due to an anti-atherogenic effect (17,36). Our findings are consistent with these results and may offer a pathogenetic explanation for the delayed effects on cardiovascular events, indicating the amelioration of metabolic and vascular markers observed at nine months of treatment.

Our study is the first to evaluate the beneficial effects of dulaglutide on both vascular health indexes such as arterial stiffness and endothelial dysfunction markers. These novel findings may explain the interplay between the improvement in metabolic variables and reduction in cardiovascular outcomes reported by a trial on the effect of dulaglutide (45) on cardiovascular outcomes. Our findings concerning surrogate vascular markers may also represent an explanation of the cardiovascular positive effects of other glucagon-like peptide 1 receptor agonists (GLP-1-RAs), such as liraglutide and semaglutide (50-57).

Activation of the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome plays an important role in high glucose-induced endothelial dysfunction in patients with type 2 diabetes mellitus (T2DM). A recent study investigated whether dulaglutide possesses a protective effect against high glucose-induced activation of the NLRP3 inflammasome. These authors showed that dulaglutide treatment prevented high glucose-induced generation of reactive oxygen species (ROS) and protein carbonyls, as well as the expression of NADPH oxidase 4 (NOX-4) in human umbilical vein endothelial cells (HUVECs) (58,59).

Another recent study compared the effect of dulaglutide and liraglutide on oxidative stress and endothelial function in patients with type 2 diabetes mellitus (T2DM). No significant differences were found in d-ROMs and logarithmic-scaled RHI (L-RHI) between the two groups after 24 weeks of treatment (60).

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given the ability of this agent class to reduce glycated
haemoglobin and associated weight loss and low risk for hypoglycaemia. Additionally, some cardiovascular outcomes trials (CVOTs) found non-inferiority for cardiovascular outcomes, with many findings of the superiority of these drugs.

A recent study of twelve-month treatment with GLP-1RA, SGLT-2i, and their combination showed greater improvement in vascular markers and effective cardiac cycles than insulin treatment in type 2 diabetes mellitus. The combined therapy as second line was superior to either insulin or GLP-1RA and SGLT-2i separately (61). Another study (62) showed that six-month treatment with liraglutide improved arterial stiffness, LV myocardial strain, LV twisting and untwisting and NT-proBNP by reducing oxidative stress in subjects with newly diagnosed T2DM.

Thus, several lines of evidence (61,62,63) have reported that newer antidiabetic drugs differentially affect endothelial function and arterial stiffness, as assessed by FMD and PWV, respectively. These findings could explain the distinct effects of these drugs on the cardiovascular risk of patients with type 2 diabetes mellitus.

However, most studies have evaluated the putative protective vascular role of liraglutide and only a few have evaluated this role for dulaglutide. No study has evaluated the role of both arterial stiffness and endothelial indexes; thus, our findings may appear original.

These findings have transformed our guidelines on the pharmacological treatment of T2D. Future prospective studies will be addressed to evaluate the relationship between the effects of GLP-1 RAs on vascular damage markers and the incidence of new cardiovascular events.

**Strengths and Limitations**

The strengths of our study include the broad and representative inclusion criteria and recruited participants, long follow-up, high retention, measurement of clinically relevant outcomes and of surrogate vascular endpoints.

A possible limitation is that we considered several endpoints (metabolic and vascular) and that we did not consider primary and secondary outcomes but some parallel aims.

**Conclusions**

Our randomized trial showed that diabetic subjects treated with conventional therapy plus 1.5 mg of subcutaneous dulaglutide, compared with subjects treated with conventional therapy alone, showed favourable metabolic effects that are associated with positive effects on vascular health markers such as arterial stiffness and endothelial function markers. We furthermore reported that, unlike some metabolic effects, such as the positive effects on FPG and HbA1c, that were observed at the three-month follow-up, other metabolic effects, such as body weight and BMI reduction and positive effects on lipid serum values, were observed only at the nine-month follow-up, similarly to the positive vascular effects on PWV, Alx, and RHI.
Thus, it is intriguing to speculate that the positive vascular effects could be strictly linked to the lipidaemic metabolic positive effects of dulaglutide and reduction of body weight with consequent modulation of related adipose-derived inflammation.

Concerning this issue, further studies will be addressed by our group to evaluate the possible effects of dulaglutide treatment on adipose-derived hormones and cytokines, such as PAI-1, adiponectin, and IL-6, that may be favourably changed by dulaglutide treatment.

**Abbreviations**

CV: cardiovascular  
GLP: glucagon-like peptide 1  
FPG: fasting plasma glucose  
HbA1c: *glycated haemoglobin*  
LDL: low-density lipoprotein  
HDL: high-density lipoprotein  
BMI: body mass index  
FMD: flow-mediated vasodilation  
RH-PAT: reactive hyperaemia peripheral arterial tonometry  
NAFLD: Non-alcoholic fatty liver disease  
eGFR: estimated glomerular filtration rate  
ESC-ESH: European Society of Cardiology-European Society of Hypertension  
BP: blood pressure  
Alx: augmentation index  
PP: pulsatory pressure  
RHI: reactive hyperaemia index  
PWV: pulse wave velocity  
NLRP3: NOD-, LRR- and pyrin domain-containing protein 3  
SBP: systolic blood pressure
DBP: diastolic blood pressure

TRLs: triglycerides-rich particles

VLDL: very-low-density lipoprotein

T2DM: type 2 diabetes mellitus

GLP-1-RA: glucagon-like peptide 1 receptor agonist

ROS: reactive oxygen species

AGEs: advanced glycation end-products

NO: nitric oxide

ICAM-1: intercellular adhesion molecule 1

VCAM-1: vascular cell adhesion molecule 1

CVOTs: cardiovascular outcomes trials

**Declarations**

**Ethics approval and consent to participate**

This protocol study was approved by the Ethics Committee of the Policlinico P. Giaccone Hospital, and all patients provided written informed consent to participate in the study and for sampling and banking of the biological material. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, and written informed consent was obtained from all the patients. A statement of ethics approval was obtained using the name of the ethics committee and reference number if appropriate

**Consent for publication**

All enrolled patients (or legal parents or guardians for children) provided consent to publish individual patient data.

**Availability of data and material**

All data and material are available on figshare (https://figshare.com/s/2fa3227c64b263f9b7cf).

**Competing interest**

All the authors have no competing interests.

**Funding**
Authors’ contributions

- Antonino Tuttolomondo: designed the study, wrote the paper, and collected and analysed the data
- Anna Cirrincione: designed and performed the study, and collected and analysed the data
- Alessandra Casuccio: performed the study
- Alessandro Del Cuore: performed the study
- Mario Daidone: performed the study
- Tiziana Di Chiara: performed the study
- Domenico Di Raimondo performed the study
- Vittoriano Della Corte: performed the study
- Carlo Domenico Madia: performed the study
- Irene Simonetta: performed the study
- Stefania Scaglione: performed the study
- Antonio Pinto: designed the study

Acknowledgements

None.

References

1. Anini Y, Brubaker PL. Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 2003; 144: 3244–3250
2. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50: 583–589, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
3. Drucker DJ, Nauck MA. Lancet. 2006 Nov 11;368(9548):1696-705.
4. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7–36) amide in type I diabetic patients. Diabetes Care 1996; 19: 580–586
5. Tong J, D’Alessio D. Give the receptor a brake: slowing gastric emptying by GLP-1. Diabetes 2014; 63: 407–409
6. Turton MD, O'Shea D, Gunn I et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69–72. 7. Gutzwiller JP, Drewe J, Göke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541–1544.
7. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728–742.

8. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37: 2149–2158.

9. Dungan KM, Povedano ST, Forst T et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384: 1349–1357.

10. Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014; 37: 2168–2176.

11. Wysham C, Blevins T, Arakaki R et al. Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37: 2159–2167.

12. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. 2002;105:576–82.

13. Ammar RF, Jr, Gutterman DD, Brooks LA, et al. Free radicals mediate endothelial dysfunction of coronary arterioles in diabetes. Cardiovasc Res. 2000;47:595–60.

14. Aanderud S, Krane H, Nordoy A. Influence of glucose, insulin and sera from diabetic patients on the prostacyclin synthesis in vitro in cultured human endothelial cells. 1985;28:641–4

15. McVeigh GE, Cohn JN. Endothelial dysfunction and the metabolic syndrome. Curr Diab Rep. 2003;3:87–92.

16. Meeking DR, Cummings MH, Thorne S, et al. Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria. Diabet Med. 1999;16:841–7.

17. Meigs JB, Hu FB, Rifai N, et al. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. 2004;291:1978–86.

18. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poultar NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22; Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

19. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poultar NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group. Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113.

20. Kuvin, A.R. Patel, K.A. Sliney, N.G. Pandian, J. Sheffy, R.P. Schnall, et al., Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude, Am. Heart J. 146 (2003) 168e174.
21. M. Hamburg, M.J. Keyes, M.G. Larson, R.S. Vasan, R. Schnabel, M.M. Pryde, et al., Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study, Circulation 2008;117 2467e2474.

22. L. Meyer, H. Tanaka, P. Palta, S. Cheng, N. Gouskova, D. Aguilar, et al., Correlates of segmental pulse wave velocity in older adults: the atherosclerosis risk in communities (ARIC) study, Am. J. Hypertens. 29 (1) (2016 Jan) 114e122.

23. Meyer ML, Tanaka H, Palta P, Cheng S, Gouskova N, Aguilar D, Heiss G. Correlates of segmental pulse wave velocity in older adults: the atherosclerosis risk in communities (ARIC) study. Am J Hypertens. 2016;29(1):114–22.

24. Lenders M, Hofschröer V, Schmitz B, Kasprzak B, Rohlmann A, Missler M, Ravenstäd H, Oberleithner H, Brand SM, Kutsche-Vihrog K, Brand E. Differential response to endothelial epithelial sodium channel inhibition ex vivo correlates with arterial stiffness in humans. J Hypertens. 2015;33(12):2455–62.

25. Tuttolomondo A, Casuccio A, Guercio G, Maida C, Del Cuore A, Di Raimondo D, Simonetta I, Di Bona D, Pecoraro R, Della Corte V, Gulotta E, Gulotta G, Pinto A. Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndrome. Cardiovasc Diabetol. 2017 Jan 6;16(1):2 .

26. Tuttolomondo A, Petta S, Casuccio A, Maida C, Della Corte V, Daidone M, Di Raimondo D, Pecoraro R, Fonte R, Cirrincione A, Zafonte R, Cabibi D, Cammà C, Di Marco V, Licata A, Magliozzo F, Marchesini G, Merlino G, Craxì A, Pinto A. Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. Cardiovasc Diabetol. 2018 Feb 16;17(1):28.

27. Tuttolomondo A, Casuccio A, Della Corte V, Maida C, Pecoraro R, Di Raimondo D, Vassallo V, Simonetta I, Amavo V, Pinto A Endothelial function and arterial stiffness indexes in subjects with acute ischemic stroke: Relationship with TOAST subtype. Atherosclerosis. 2017 Jan;256:94-99.

28. Nagaike H, Ohara M, Kohata Y, Hiromura M, Tomoyasu M, Takada M, Yamamoto T, Hayashi T, Fukui T, Hirano T Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study. Diabetes Ther. 2019 Feb;10(1):215-228.

29. World Medical Association. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925–926.

30. American Diabetes Association: Clinical practice recommendations 2000. Diabetes Care 2001; 23(Suppl. 1): S1–S116

31. ESH/ESC Guidelines for the management of arterial hypertension TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013, 31:1281–1357.

32. Palatini P, Benetos A, Grassi G, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J
33. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American association of clinical endocrinologists’ guidelines for management of Dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18(Suppl 1):1–78.

34. Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015 Oct;17(10):974-83.

35. Dungan KM, Povedano ST, Forst T, González JG, Atisso C, Sealls W, Fahrbach JL. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014 Oct 11;384(9951):1349-57. doi: 10.1016/S0140-6736(14)60976-4. Epub 2014 Jul 10. Erratum in: Lancet. 2014 Oct 11:384(9951):1348.

36. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29:1260–1267.

37. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3.

38. Chahil TJ, Ginsberg HN. Diabetic dislypidemia. Endocrinol Metab Clin North Am 2006; 35: 491-510.

40. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014 Dec;35(6):992-1019.

41. Hein GJ, Baker C, Hsieh J, Farr S, Adeli K. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes. 2013 Feb;62(2):373-8.

42. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–138.

43. Kannel WB, Dawber TR, Friedman GD, Glennon WE, McNamara PM. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham Study. Ann Intern Med. 1964; 61:888–899,
44. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Boren J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgozoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38:2459–2472.

45. Ceriello A, Novials A, Canivell S, et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care. 2014;37:1938–43.

46. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Sillje HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 2010;30:1407–14.

47. Fuechtenbusch M, Aberle J, Heitmann E, Nicolay C, Jung H. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups. Diabetes Obes Metab. 2019 Jun;21(6):1340-1348.

48. Virdis A, Duranti E, Rossi C, Dell'Agnello U, Santini E, Anselmino M, Chiarugi M, Taddei S, Solini A. Tumour necrosis factor-alpha participates on the endothelin-1/nitric oxide imbalance in small arteries from obese patients: role of perivascular adipose tissue. Eur Heart J. 2015 Apr 1;36(13):784-94.

49. Ohara M, Nagaike H, Goto S, et al. Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;139:253–61.

50. Wright E., J . L. Scism-Sacon, C. Glass “Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia” Journal compilation 2006 Blackwell Publishing Ltd Int J Clin Pract, March 2006, 60, 3, 308–314

51. Djindjic B, Kostic T, Radovanovic Z, Djindjic N, Lazovic M, Zivic M, Perisic Z, Krstic N. The contributions of fasting and postprandial blood glucose increments to oxidative stress and inflammation in dyslipidemic type 2 diabetic patients with stable ischemic heart disease. Int J Cardiol. 2017 Jan 15;227:611-616.

52. Loria CM, Liu K, Lewis CE, Hulley SB, Sidney S, Schreiner PJ, Williams OD, Bild DE, Detrano R. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA study. J Am Coll Cardiol. 2007; 49:2013–2020

53. Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J. 2010 Oct;31(19):2338-50; Ji X, Zhao H, Wang M, Li Y, Zhang C, Wang X. Study of correlations between metabolic risk factors, PWV and hypertension in college students. Clin Exp Hypertens. 2020 Feb 4:1-5.
54. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydéń L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurtchschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019 Jul 13;394(10193):121-130.

55. Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785.

56. Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019 Oct;42(10):1912-1920.

57. Avgerinos I, Michailidis T, Liakos A, Karagiannis T, Matthews DR, Tsapas A, Bekiari E. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2020 Mar;22(3):335-345.

58. C. Ferdinand, W. B. White, D. A. Calhoun et al., “Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus,” Hypertension, vol. 64, no. 4, pp. 731–737, 2014.

59. R. Tuttle, T. D. McKinney, J. A. Davidson, G. Anglin, K. D. Harper, and F. T. Botros, “Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials,” Diabetes, Obesity and Metabolism, vol. 19, no. 3, pp. 436–441, 2017.

60. Luo X, Hu Y, He S, Ye Q, Lv Z, Liu J, Chen X. Dulaglutide inhibits high glucose-induced endothelial dysfunction and NLRP3 inflammasome activation. Arch Biochem Biophys. 2019 Aug 15;671:203-209.

61. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–138.

62. Nagaike H, Ohara M, Kohata Y, Hiromura M, Tomoyasu M, Takada M, Yamamoto T, Hayashi T, Fukui T, Hirano T. Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study. Diabetes Ther. 2019 Feb;10(1):215-228.

63. Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients
With Type 2 Diabetes Mellitus After 12-Month Treatment. J Am Heart Assoc. 2020 May 5;9(9):e015716.

64. Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, Georgiou D, Andreadou I, Parissis J, Triantafyllidi H, Lekakis J, Iliodromitis E, Dimitriadis G, Ikonomidis I. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovasc Diabetol. 2018 Jan 8;17(1):8.

65. Batzias K, Antonopoulos AS, Oikonomou E, Siasos G, Bletsa E, Stampouloglou PK, Mistakidi CV, Noutsou M, Katsiki N, Karopoulos P, Charalambous G, Thanopoulou A, Tentolouris N, Tousoulis D. Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. J Diabetes Res. 2018 Dec 4;2018:1232583

Tables

**Table 1:** general, demographic and laboratory variables in subjects treated with dulaglutide vs controls (conventional therapy)
| Variables                               | subjects treated with conventional therapy + dulaglutide (n=56) | Controls (conventional therapy) (n=56) | P  |
|----------------------------------------|---------------------------------------------------------------|---------------------------------------|----|
| Age (years) (mean ± SD)                | 69.7 ± 8.6                                                    | 67.6 ± 5.1                           | 0.111 |
| M/F (n/%)                              | 24/32 (42.8/57.2)                                            | 21/35 (37.5/62.5)                    | 0.700 |
| SBP (mm/Hg) (mean ± SD)                | 137.8 ± 12.1                                                 | 133.9 ± 12.3                        | 0.087 |
| DBP (mm/Hg) (mean ± SD)                | 76.3 ± 12.3                                                  | 79.8 ± 7.7                           | 0.071 |
| Weight (Kg) (mean ± SD)                | 75.7 ± 8.5                                                   | 76.6 ± 7.5                           | 0.562 |
| BMI (kg/m2) (mean ± SD)                | 27.6 ± 3.4                                                   | 27.9 ± 3.2                           | 0.563 |
| HR (bpm) (mean ± SD)                   | 76.6 ± 11.1                                                  | 79.3 ± 15.8                          | 0.299 |
| Total cholesterol (mg/dl) (mmol/L) (mean ± SD) | 160.9± 20.5/4.2±0.5                                         | 167.8± 25.8/4.3±0.7                  | 0.121 |
| HDL cholesterol (mmol/L) (mean ± SD)   | 37.4 ± 4.3/0.9±0.1                                           | 37.5 ± 4.5/0.9±0.2                   | 0.961 |
| LDL cholesterol (mmol/L) (mean ± SD)   | 102.7 ± 11.6/2.6±0.3                                         | 104.5 ± 13.5/2.7±0.4                 | 0.439 |
| Triglycerides (mmol/L) (mean ± SD)     | 139.2 ± 13.6/1.6±0.2                                         | 138.9 ± 13.6/1.6±0.2                 | 0.910 |
| FPG (mg/dl/mmol/L (mean ± SD)          | 147.6±32.6/8.2±1.2                                          | 144.7±31.5/8.1±1.8                   | 0.626 |
| HbA1C (% (mean ± SD)                    | 7.4 ± 0.7                                                    | 7.2 ± 0.6                            | 0.101 |
| eGFR CKD-EPI (mL/min per 1·73 m) (mean ± SD) | 77.4 ± 11.2                                                  | 76.1 ± 16.9                          | 0.640 |
| Microalbuminuria (mg/24 h) (mean ± SD) | 80.9 ± 20.9                                                  | 73.1 ± 29.2                          | 0.107 |
| RHI (mean ± SD)                        | 1.7 ± 0.4                                                    | 1.8 ± 0.7                            | 0.275 |
| PWV (m/sec) (mean ± SD)                | 11.2±0.9                                                    | 10.9±0.8                             | 0.193 |
| Aix (%) (mean ± SD)                    | 105.6± 6.9                                                  | 103.9±4.4                            | 0.121 |
| Hypertension (n/%)                     | 45/80.3                                                      | 35/62.5                              | 0.700 |
| Diabetes (n/%)                         | 56/100                                                       | 56/100                               | -    |
| Duration of diabetes (years) (mean ± SD) | 10.4 ± 3.3                                                  | 10.2 ± 4.0                           | 0.773 |
| Dyslipidaemia (n/%)                    | 32(57.1)                                                     | 29 (51.8)                            | 0.704 |
| Hypercholesterolaemia (n/%)            | 31 (55.3)                                                    | 27 (48.2)                            | 0.570 |
| Smoking (n/%)                          | 12 (21.4)                                                    | 13 (23.2)                            | 1.0   |
| Microalbuminuria                       | 12 (21.4)                                                    | 11 (19.6)                            | 1.0   |
| Macroalbuminuria                       | 4 (7.1)                                                      | 3 (5.4)                              | 1.0   |
| Metformin (n/%)                        | 50 (89.3)                                                    | 49 (87.5)                            | 1.0   |
| Sulfonyluree (n/%)                     | 31 (55.3)                                                    | 30 (53.6)                            | 1.0   |
| Insulin (n/%)                          | 12 (21.4)                                                    | 11 (19.6)                            | 1.0   |
| ACEI (n/%)                             | 28(50.0)                                                     | 32(57.1)                             | 0.569 |
| Beta blockers (n/%)                    | 28(50.0)                                                     | 24(42.8)                             | 0.570 |
| CCB (n/%)                              | 21(37.5)                                                     | 22(39.3)                             | 1.0   |
| Antiplatelets (n/%)                    | 23(41.1)                                                     | 18(32.1)                             | 0.432 |
| Anticoagulants (n/%)                   | 30(53.6)                                                     | 30(53.6)                             | 1.0   |
| Diuretics (n/%)                        | 27(48.2)                                                     | 30(53.6)                             | 0.705 |
| Statins (n/%)                          | 22(39.3)                                                     | 16(28.6)                             | 0.318 |

Data are expressed as mean (SD), n (%),
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; HR: heart rate; LDL: low density lipoprotein; HDL: High Density Lipoprotein; FPG: fasting plasma glucose; HbA1C: glycated hemoglobin; PWV: pulse wave velocity, AIX: augmentation index; E-GFR: Estimated Glomerular Filtration Rate
SGLT2: sodium-glucose co-transporter-2. ACE=angiotensin-converting enzyme. ARB: angiotensin-receptor blocker. HbA1c: glycated haemoglobin A1c. eGFR=estimated glomerular filtration rate.

Table 2: Intergroup analysis of metabolic and vascular variables in patients treated with dulaglutide and controls at a three and nine month follow-up
| Variable | Three months follow-up | Nine months follow-up |
|----------|------------------------|-----------------------|
| SBP (mmHg) (mean±SD) | | |
| subjects treated with dulaglutide | 134.9 ± 10.9 | 129.7 ± 10.7 |
| controls | 133.7 ± 16.6 | 132.7 ± 16.7 |
| P | 0.653 | 0.264 |
| DBP (mmHg) (mean±SD) | | |
| subjects treated with dulaglutide | 73.2 ± 9.9 | 71.8 ± 9.2 |
| controls | 75.9 ± 9.1 | 75.9 ± 9.7 |
| P | 0.138 | 0.026 |
| Weight (Kg) (mean±SD) | | |
| subjects treated with dulaglutide | 73.1 ± 7.6 | 68.9 ± 5.6 |
| controls | 76.6 ± 7.1 | 76.3 ± 13.8 |
| P | 0.014 | 0.015 |
| BMI (kg/m2) (mean±SD) | | |
| subjects treated with dulaglutide | 26.9 ± 3.4 | 25.2 ± 3.6 |
| controls | 26.6 ± 5.0 | 27.8 ± 5.1 |
| P | 0.741 | 0.003 |
| HR (bpm) (mean±SD) | | |
| subjects treated with dulaglutide | 75.6 ± 6.0 | 75.1 ± 5.3 |
| controls | 78.7 ± 12.5 | 77.7 ± 12.5 |
| P | 0.097 | 0.161 |
| Total cholesterol (mg/dl) (mmol/L) (mean±SD) | | |
| subjects treated with dulaglutide | 160.3 ± 21.2/4.3±0.7 | 152.3 ± 22.4/3.94±0.58 |
| controls | 165.2± 26.3/4.2±0.6 | 163.3 ± 21.5/4.22±0.56 |
| P | 0.284 | 0.009 |
| HDL cholesterol (mg/dl) (mmol/L) (mean±SD) | | |
| subjects treated with dulaglutide | 36.4 ± 4.3/0.9±0.1 | 38.3 ± 5.7/0.99±0.15 |
| controls | 36.7 ± 4.3/0.9±0.1 | 36.9 ±4.7/0.95±0.11 |
| P | 0.607 | 0.135 |
| LDL cholesterol (mg/dl) (mmol/L) (mean±SD) | | |
| subjects treated with dulaglutide | 101.8± 10.6 /2.6±0.2 | 96.0 ± 9.1/2.48± 0.24 |
| controls | 103.8 ±11.9/2.68±0.31 | 103.2 ±10.8/2.67±0.28 |
| P | 0.393 | <0.0005 |
| triglycerides (mg/dl) (mmol/L) (mean±SD) | | |
| subjects treated with dulaglutide | 138.1 ± 13.2/1.5±0.1 | 137.5 ± 18.9/1.55±0.21 |
| controls | 138.0 ± 15.9/1.56±0.18 | 138.1 ± 18.9/2.72±0.42 |
| P | 0.971 | 0.878 |
| FPG (mg/dl/mmol/l) (mean±SD) | | |
| subjects treated with dulaglutide | 131.2 ± 21.9/7.2±1.2 | 119.3 ± 14.3/6.65±1.05 |
| controls | 146.2 ±29.5/8.13±1.64 | 145.5 ±29.6/8.09±1.64 |
| P | 0.003 | <0.0005 |
| HBA1C (media± DS) | | |
| subjects treated with dulaglutide | 6.5 ± 0.5 | 6.2± 0.3 |
| Controlli | 7.0 ± 0.5 | 6.9 ± 0.5 |
| P | <0.0005 | <0.0005 |
| GFR CKD-EPI (mean±SD) | | |
| subjects treated with dulaglutide | 76.7 ± 10.5 | 76.7 ± 9.8 |
| controls | 76.5 ± 16.2 | 76.5 ± 16.2 |
|                                | subjects treated with dulaglutide | controls | P     |
|--------------------------------|----------------------------------|----------|-------|
| Microalbuminuria (mg/24H) (mean±SD) | 80.1 ± 16.6                     | 82.8 ± 18.5 | 0.432 |
|                                 | 79.1 ± 9.0                       | 82.5 ± 9.3 | 0.05  |
| RHI (mean±SD)                   | 1.8 ± 0.4                        | 2.0 ± 0.4  | 0.901 |
|                                 | 1.8 ± 0.4                        | 2.0 ± 0.4  | 0.023 |
| PWV (m/sec) (mean±SD)           | 10.8±0.8                         | 10.6±0.8  | 0.376 |
|                                 | 10.9±0.6                         | 11.0±0.6  | 0.015 |
| AIX (%)( media± DS)             | 103.1±6.7                        | 101.8±5.3 | 0.116 |
|                                 | 101.4±3.6                        | 101.9±3.8 | 0.937 |

Data are expressed as mean (SD), n (%),
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; HR: heart rate; LDL: low density lipoprotein; HDL: High Density Lipoprotein; FPG: fasting plasma glucose; HbA1C: glycated hemoglobin; PWV: pulse wave velocity, AIX: augmentation index; E-GFR: Estimated Glomerular Filtration Rate

P = p value of intergroup differences assessed by independent Student t test for continuous parameters

Table 3: Intragroup analysis of patients treated with subjects treated with conventional therapy + dulaglutide at a three and nine month follow-up
| abile                      | baseline | Three months | nine months | P       |
|----------------------------|----------|--------------|-------------|---------|
| SBP (mm/Hg) (mean±SD)      | 137.8 ± 12.1 | 134.9 ± 10.9 | 129.7 ± 10.7 | <0.0005*<br>0.012^ |
| DBP (mm/Hg) (mean±SD)      | 76.3 ± 12.3 | 73.2 ± 9.9   | 71.9 ± 9.2  | 0.03*   |
| wt (Kg) (mean±SD)          | 75.7 ± 8.5  | 73.1 ± 7.6   | 68.9 ± 8.8  | 0.02°   <br><0.0005*<br>0.008^ |
| t/g/m2) (mean±SD)          | 27.6 ± 3.4  | 26.9 ± 3.4   | 25.2 ± 3.6  | <0.0005*<br>0.01^ |
| BMI (mean±SD)              | 76.6 ± 11.1 | 75.6 ± 6.0   | 75.1 ± 5.3  | 0.58    |
| cholesterol (mmol/L)       | 160.9 ± 20.5 /4.2±0.5 | 160.3 ± 21.2/4.3±0.7 | 152.3 ± 22.4/3.9±0.5 | 0.04*   |
| cholesteroll (mmol/L)      | 37.4 ± 4.3/0.9±0.1 | 36.4 ± 4.3/0.9±0.1 | 38.3 ± 6.1/0.9±0.1 | 0.79    |
| cholesterol (mmol/L)       | 102.7 ± 11.6/2.6±0.3 | 101.8 ± 10.6/2.6±0.2 | 96.0 ± 9.1/2.4±0.2 | 0.001*<br>0.002^ |
| cerides (mmol/L)           | 139.2 ± 13.6/1.6±0.2 | 138.1 ± 13.2/1.5±0.1 | 137.5 ± 18.9/1.5±0.2 | 1.0     |
| mg/dl/mmol/l               | 147.6±32.6 /8.2±1.2 | 131.2±21.9/7.2±1.2 | 119.3±14.3/6.6±1.0 | 0.002*<br><0.0005*<br>0.001^ |
| C (%) (media± DS)          | 7.4 ± 0.7   | 6.5 ± 0.5    | 6.2 ± 0.3   | <0.0005*<br>0.0005°<br>0.001^ |
| KD-EPI (mm±SD)             | 77.4 ± 11.2 | 76.7 ± 10.5  | 76.7 ± 9.8  | 0.1     |
| albuminuria (24h) (mean±SD)| 80.9 ± 20.9 | 80.1 ± 16.6  | 80.1 ± 16.6 | 0.35    |
| mean±SD)                   | 1.7 ± 0.4   | 1.8 ± 0.4    | 2.0 ± 0.4   | <0.0005* |
| m/sec) (mean±SD)           | 11.2±0.9    | 10.8±0.8     | 10.6±0.8    | 0.02°   <br><0.0005* |
| %) (mean±SD)               | 105.6±6.9   | 103.1±6.7    | 101.8±5.3   | 0.001*  |

*9 months vs baseline; ^ 9 months vs 3 months; ° 3 months vs baseline;  
Data are expressed as mean (SD), n (%).  
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; HR: heart rate; LDL: low density lipoprotein; HDL: High Density Lipoprotein; FPG: fasting plasma glucose; HbA1C: glycated hemoglobin; PWV: pulse wave velocity, AIX: augmentation index; E-GFR: Estimated Glomerular Filtration Rate  
P= p value of intragroup differences assessed by independent Student t test for continuous parameters.